AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants
Phase 1
Completed
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Biological: Placebo (Cohort 3)Biological: Placebo (Cohort 2)Biological: AZD3152 (Cohort 3)Biological: AZD3152 (Cohort 2)Biological: AZD3152 (Cohort 1)Biological: Placebo (Cohort 1)
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05932641
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
OPTIMISE-CKD Drug Utilization
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2682052
- Registration Number
- NCT05932901
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 662
- Registration Number
- NCT05933044
- Locations
- 🇨🇦
Queen Elizabeth (QE) II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT05926349
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT05924880
- Locations
- 🇨🇳
Research Site, Xiamen, China
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Phase 3
Recruiting
- Conditions
- Systemic SclerosisScleroderma
- Interventions
- Combination Product: Anifrolumab (blinded)Drug: Placebo (blinded)Combination Product: Anifrolumab (unblinded, open label)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 306
- Registration Number
- NCT05925803
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT05925530
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Tezepelumab PRO Study
Active, not recruiting
- Conditions
- Asthma
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 92
- Registration Number
- NCT05922891
- Locations
- 🇯🇵
Research Site, Yonago, Japan
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
Active, not recruiting
- Conditions
- Ovarian Cancer
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT05918042
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China
Completed
- Conditions
- COVID-19
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT05917951
- Locations
- 🇨🇳
(2) Ruijin-Hainan Hospital Shanghai Jiaotong University School of Medicine (Hainan Boao Research Hospital), Qionghai, Hainan, China
© Copyright 2025. All Rights Reserved by MedPath